VIEWPOINTS

Tim Clackson, President & CEO of Theseus Pharmaceuticals, Shares Insights on its Pan-Variant Inhibitor Therapies to Treat Cancer

Shots: Tim spoke about the development of THE-349, a fourth-generation small molecule for the treatment of EGFR-mutant NSCLC Tim also talked about Thesus’ other small molecule, THE-630 in gastrointestinal stromal tumors (GIST) being evaluated in a P-I/II dose-escalation and expansion study The interview gives an understanding of how Thesus is developing different treatment options to…

November 28, 2022

Herson Quiñones, VP at GSK Shares Insights on the FDA Approval of Benlysta for Pediatric Patients with Active Lupus Nephritis

Shots: Herson spoke about the approval of Benlysta by the US FDA for the treatment of children aged 5 to 17 with active lupus nephritis (LN) which often causes increased complications, hospitalizations, and mortality rates in children He also talked about the etiology & epidemiology of lupus nephritis and how this disease is affecting millions…

November 22, 2022

Dr. Navdeep Tangri & Helen Yeh Shares Insights from the Data Presented at ASN Kidney Week 2022 on the Importance of Earlier Screening & Diagnosis of Chronic Kidney Disease

Shots: Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney disease Helen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patients The…

November 21, 2022

Emily Browder, Head of Global Communications, Merz Aesthetics Shares Insights on its New Corporate Visual Identity

Shots: Emily spoke about the launch of the new visual identity of Merz Aesthetics. The identity is built on the idea to create a cohesive and clear visual identity for Merz Aesthetics that reflects who they are and the purpose to fuel confidence The brightness of this new identity includes shades of orange, yellow, green,…

November 15, 2022

Dr. Susana Banerjee, Medical Oncologist at The Royal Marsden Shares Insights from the SOLO-1 P-III Trial of Lynparza in Patients with BRCA Mutated Ovarian Cancer

Shots: Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22 Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…

November 14, 2022

Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

Shots: Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID) The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…

November 9, 2022

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots: Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries The interview summarizes how Shionogi is advancing by developing medicines to treat serious…

November 7, 2022

Martin Kilsgård, Head of Product at Trialbee, Shares Insights from the Launch of Trialbee Honey™ Analytics at DPHARM 2022

Shots: Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platform He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…

November 2, 2022

Natalie Shiff, Associate Medical Director, Janssen Rheumatology Shares Insights from the FDA Approval of Stelara to Treat Pediatric Patients with Active Psoriatic Arthritis

Shots: Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara The interview gives an understanding of how Janssen is advancing…

October 31, 2022

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots: Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2 activating mutations for treatment with ENHERTU Garret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographies The interview highlights how Thermo Fisher is working to develop accessible CDx solutions…

October 25, 2022